Q: Hi, Your feedback about DTC please.
5i Research Answer:
DTC is a $116.6M company that operates in the biotech space. It recently announced that its ARM vaccine cured 100% of animals with pre-established lymphoma. The company is pre-revenue and primarily issues shares to fund its operations. Its balance sheet is fairly thin, with an equity deficit of $2.1M and a cash balance of $0.2M. Insiders own roughly 5%, and it is not without potential, but we would consider the name to be a higher-risk company and we would like to see the company materialize sales before entering here.